Annals of oncology : official journal of the European Society for Medical Oncology
-
Multicenter Study Clinical Trial
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly established chemotherapeutic regimens and the aim of treatment is palliation with improvement in the quality of life. ⋯ Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM. The use of this drug should be explored further in an adjuvant setting and in combination with other agents.